As shortages of vital medicines stretch into another year, a growing chorus in health care says mergers are not the remedy. Hospitals, pharmacists, and policy experts warn that buying power and bigger balance sheets won’t solve fragile supply chains or thin margins that drive shortages in the first place.
The strain is most visible in sterile injectable generics, including common anesthesia agents and cancer drugs. Hospitals across the United States report delayed surgeries and treatment changes while they hunt for alternatives. The timing is urgent, with national shortage tallies near record highs and patient care on the line.
A Shortage Years in the Making
Drug shortages have surged since the pandemic, but the roots run deeper. Quality failures at key plants, concentration of suppliers for active ingredients, and contracts that prize the lowest price have left little slack in the system. When one link breaks, the market struggles to adjust.
The American Society of Health-System Pharmacists has tracked the trend. Earlier this year, it reported the highest number of active shortages since it began keeping records in 2001. Oncologists continue to report recurring gaps in supplies of carboplatin and cisplatin, two mainstays of chemotherapy.
Hospital buyers say the market is especially brittle for older, low-cost injectables. These products are hard to make, require sterile facilities, and yield slim profits. A single plant shutdown can ripple nationwide.
Why Mergers Fall Short
But consolidation will not ease the shortage.
That view reflects a simple calculus: ownership changes do not create new capacity, fix quality issues, or diversify sources of key ingredients. Several analysts note that the number of firms capable of producing sterile injectables at scale is already small. Fewer competitors can mean fewer backup options when trouble hits.
Economists also point to buyer consolidation. Three large group purchasing organizations negotiate contracts for most U.S. hospitals. Their focus on the lowest unit price has pushed manufacturers to cut costs, sometimes at the expense of redundancy and preventive maintenance.
“If contracts don’t reward reliability, plants won’t invest in it,” said one hospital pharmacy leader. “When anything goes wrong, there’s no cushion.”
Hospitals Caught in the Middle
Care teams report daily workarounds. Pharmacists substitute second-line therapies, split doses, or delay non-urgent procedures. Each step adds administrative load and clinical risk.
One oncology nurse described spending hours chasing shipments that used to be routine. “You can feel the stress in the infusion room,” she said. “Patients ask why a standard drug isn’t here. There isn’t a simple answer.”
Manufacturers counter that raising prices to fund redundancy is difficult in a market where contracts are locked for years. They also note that qualifying new production lines requires regulatory oversight and time.
The Policy and Market Fixes
Federal agencies have offered a menu of changes. Recent White House and FDA reports call for early-warning systems, stronger reporting on supply chain risks, and payment models that reward steady supply, not only the cheapest bid.
- Create contracts that pay premiums for proven reliability and quality.
- Support multiple qualified suppliers for essential medicines and ingredients.
- Offer incentives for advanced manufacturing and domestic capacity.
- Require transparent reporting on production sites and inventory levels.
- Build strategic buffers for medicines with no easy substitutes.
Some health systems are experimenting with long-term contracts that include reliability clauses. A few have invested in nonprofit manufacturers to secure supplies of critical generics. Early results suggest more stable deliveries, though at modestly higher costs.
What to Watch Next
Experts say the next 12 months will test whether policy shifts change behavior. If purchasers pay for resilience, manufacturers may bring idle lines back online, qualify second sites, or adopt processes that reduce contamination risks.
Still, the core risk remains concentration. Many active ingredients come from a small number of overseas plants. Until there are more qualified sources, any disruption can echo across hospitals.
For patients and clinicians, the measure of progress is simple: fewer substitutions and fewer delays. That will come from added capacity, better quality, and smarter contracts—changes that mergers alone cannot deliver.
The path forward is clear enough. Focus on reliability as a metric, diversify supplies, and build modest buffers for the most vulnerable drugs. If those steps take hold, the cycle of recurring shortages could finally begin to ease.
